Krystal Biotech (KRYS)
Commercializes VYJUVEK and develops redosable genetic medicines across multiple organ systems.
$338.38
vs last close−12.50 (−3.56%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 42 | 45 | 70 | 84 | 91 | 88 | 96 | 98 | 107 | 116 | 119 |
| Cost of revenue | 0 | 4 | 2 | 6 | 7 | 5 | 5 | 7 | 6 | 11 | 6 | 6 |
| Gross profit | 8 | 38 | 43 | 64 | 77 | 86 | 83 | 89 | 92 | 96 | 110 | 113 |
| 34 | 35 | 50 | 56 | 55 | 45 | 47 | 50 | 51 | 52 | 56 | 54 | |
| Research & development | 11 | 11 | 11 | 16 | 14 | 14 | 14 | 14 | 13 | 16 | 15 | 15 |
| 24 | 23 | 26 | 28 | 29 | 31 | 33 | 35 | 38 | 41 | 41 | 40 | |
| Selling & marketing | 0 | −50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 24 | 74 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 | 0 |
| Other expenses | 0 | 0 | 13 | 13 | 13 | 0 | 0 | 0 | 0 | −6 | 0 | 0 |
| Operating income | −26 | 3 | −7 | 9 | 22 | 41 | 36 | 39 | 41 | 44 | 54 | 58 |
| 107 | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 8 | 8 | |
| Interest income | 7 | 8 | 8 | 7 | 7 | 7 | 7 | 7 | 7 | −14 | 8 | 8 |
| Other non-operating income | 0 | −8 | −13 | −13 | −13 | −7 | −7 | −7 | −7 | 7 | −8 | −8 |
| Income before tax | 81 | 11 | 1 | 16 | 30 | 49 | 44 | 47 | 48 | 51 | 61 | 66 |
| Income tax expense | 0 | 2 | 0 | 0 | 3 | 3 | 8 | 8 | −31 | 0 | 6 | 11 |
| Net income from continuing operations | 81 | 9 | 1 | 16 | 27 | 45 | 36 | 38 | 79 | 51 | 56 | 55 |
| Net income | 81 | 9 | 1 | 16 | 27 | 45 | 36 | 38 | 79 | 51 | 56 | 55 |
| EPS, basic | $2.88 | $0.31 | $0.03 | $0.54 | $0.95 | $1.58 | $1.24 | $1.33 | $2.74 | $1.77 | $1.91 | $1.85 |
| EPS, diluted | $2.79 | $0.30 | $0.03 | $0.53 | $0.91 | $1.52 | $1.20 | $1.29 | $2.66 | $1.70 | $1.83 | $1.79 |
| Weighted average shares, basic | 28 | 28 | 28 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 30 |
| Weighted average shares, diluted | 29 | 29 | 29 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 31 | 31 |
| EBITDA | −25 | 12 | 7 | 23 | 36 | 50 | 45 | 48 | 50 | 40 | 63 | 66 |
| Depreciation & amortization | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 |
| EBIT | −26 | 11 | 6 | 21 | 35 | 49 | 44 | 47 | 48 | 38 | 61 | 66 |